|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects chemical synthesis |
ISO |
CYP3A4 protein affects the chemical synthesis of 6 beta-hydroxycortisol |
CTD |
PMID:15941677 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[[ABCC1 gene mutant form results in increased susceptibility to Testosterone deficiency] which results in decreased hydroxylation of Testosterone] which results in decreased chemical synthesis of 6 beta-hydroxytestosterone |
CTD |
PMID:22522787 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases chemical synthesis multiple interactions |
EXP ISO |
CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone [[CYP3A4 protein co-treated with NADP] results in increased oxidation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [CYP3A4 mRNA results in increased metabolism of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [CYP3A4 protein results in increased metabolism of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; [Meclizine results in decreased activity of CYP3A4 protein] which results in decreased chemical synthesis of 6 beta-hydroxytestosterone; erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]; fipronil promotes the reaction [[CYP3A4 protein results in increased metabolism of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Ketoconazole inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; NADP deficiency inhibits the reaction [erdafitinib inhibits the reaction [[CYP3A4 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]]; notopterol inhibits the reaction [[CYP3A4 protein results in increased metabolism of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]; obeticholic acid inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Troleandomycin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Verapamil inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone] [CYP3A4 protein results in increased metabolism of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; isobavachalcone inhibits the reaction [[CYP3A4 protein results in increased metabolism of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone] |
CTD |
PMID:12401345 PMID:16595712 PMID:17084830 PMID:19135037 PMID:20233841 PMID:20863320 PMID:21915887 PMID:23850985 PMID:26239802 PMID:26739624 PMID:27836570 PMID:27939613 PMID:28238727 PMID:29555536 PMID:30914192 PMID:31102695 PMID:31870919 PMID:32198085 PMID:34189909 PMID:35366062 PMID:35748891 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases chemical synthesis multiple interactions |
ISO |
CYP3A5 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone [CYP3A5 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone; erdafitinib inhibits the reaction [[CYP3A5 protein results in increased hydroxylation of Testosterone] which results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Meclizine inhibits the reaction [CYP3A5 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone] |
CTD |
PMID:26239802 PMID:31102695 PMID:34189909 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein] |
CTD |
PMID:29412148 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein] |
CTD |
PMID:29412148 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases secretion |
ISO |
AHR gene mutant form results in increased secretion of hyodeoxycholic acid |
CTD |
PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions |
EXP |
[CYP2D6 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of hyodeoxycholic acid |
CTD |
PMID:18039809 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP3A4 protein results in increased hydroxylation of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid; [CYP3A4 protein results in increased metabolism of Lithocholic Acid] which results in increased abundance of hyodeoxycholic acid |
CTD |
PMID:19487251 PMID:36473578 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases abundance |
ISO |
HSD11B1 gene mutant form results in increased abundance of hyodeoxycholic acid |
CTD |
PMID:25061560 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation multiple interactions affects metabolic processing increases glycosylation |
ISO |
UGT2B7 protein alternative form results in increased glucuronidation of hyodeoxycholic acid; UGT2B7 protein results in increased glucuronidation of hyodeoxycholic acid [Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased metabolism of hyodeoxycholic acid UGT2B7 protein affects the metabolism of hyodeoxycholic acid UGT2B7 protein results in increased glycosylation of hyodeoxycholic acid |
CTD |
PMID:8423545 PMID:8517101 PMID:12527334 PMID:21415305 PMID:36473578 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression multiple interactions |
EXP |
tauromuricholic acid results in increased expression of ABCB11 protein tauromuricholic acid results in increased expression of and results in increased activity of ABCB11 protein |
CTD |
PMID:11672435 PMID:12644037 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression multiple interactions |
EXP |
tauromuricholic acid results in increased expression of ABCC2 protein tauromuricholic acid results in increased expression of and results in increased activity of ABCC2 protein |
CTD |
PMID:11672435 PMID:12644037 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
EXP |
tauromuricholic acid results in increased expression of ABCC3 protein |
CTD |
PMID:11672435 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases secretion increases abundance |
ISO |
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin affects the secretion of tauromuricholic acid] AHR gene mutant form results in increased secretion of tauromuricholic acid AHR gene mutant form results in increased abundance of tauromuricholic acid |
CTD |
PMID:29452137 PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL2 mRNA |
CTD |
PMID:22098667 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of CXCL1 mRNA |
CTD |
PMID:22098667 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of tauromuricholic acid |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Taurocholic Acid co-treated with muricholic acid co-treated with tauromuricholic acid] results in increased expression of ICAM1 mRNA |
CTD |
PMID:22098667 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il10 |
interleukin 10 |
increases abundance |
ISO |
IL10 gene mutant form results in increased abundance of tauromuricholic acid |
CTD |
PMID:27580383 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects abundance |
ISO |
NR1H4 protein affects the abundance of tauromuricholic acid |
CTD |
PMID:30556042 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions increases abundance |
ISO |
[PPARA gene mutant form results in increased susceptibility to Clofibrate] which results in increased abundance of tauromuricholic acid; PPARA gene mutant form inhibits the reaction [Gemfibrozil results in increased abundance of tauromuricholic acid] PPARA gene mutant form results in increased abundance of tauromuricholic acid |
CTD |
PMID:24385052 PMID:29175453 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
EXP |
tauromuricholic acid results in increased expression of SLC10A2 protein |
CTD |
PMID:11672435 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Smad3 |
SMAD family member 3 |
increases abundance |
ISO |
SMAD3 protein results in increased abundance of tauromuricholic acid |
CTD |
PMID:23034213 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|